Popular search terms:
Search Results Label
36 results found-
Seqirus Presents Key Insights on Influenza Vaccines at the Canadian Immunization Conference 2020
https://www.seqirus.ca/news/seqirus-presents-key-insights-on-influenza-vaccines -
Vaccination with AGRIFLU® (influenza vaccine, surface antigen, inactivated) cannot cause influenza because the vaccine does not contain live virus.
https://www.seqirus.ca/-/media/seqirus-canada/docs-en/2020-agriflu-product-monograph--revised-23oct2020.pdf -
Reproductive and developmental toxicology data from trivalent influenza vaccines do not predict an increased risk of developmental abnormalities.
https://www.seqirus.ca/-/media/seqirus-canada/docs-en/2020-flucelvax-productmonograph.pdf -
Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines.
https://www.seqirus.ca/-/media/seqirus-canada/docs-fr/2020-agriflu-monographie-de-produit-revised-26oct2020.pdf -
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.seqirus.ca/ -
Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines.
https://www.seqirus.ca/-/media/seqirus-canada/docs-en/2020-fluad-product-monograph.pdf -
No interaction studies have been performed on interaction between influenza vaccines in general and other vaccines or medications.
https://www.seqirus.ca/-/media/seqirus-canada/docs-en/2020-afluria-tetra-product-monograph.pdf -
Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.seqirus.ca/our-company -
Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines.
https://www.seqirus.ca/-/media/seqirus-canada/docs-fr/2020-fluad-monographie-de-produit--2020-oct-23.pdf -
Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine
https://www.seqirus.ca/news/seqirus-announces-health-canada-approval-of--first-cell-based-seasonal-influenza-vaccine